{
  "id": 13134861,
  "title": "City Therapeutics targets $158M IPO; Iambic seeks $135M Nasdaq debut",
  "url": "https://urgent.news/2026/10/09/city-therapeutics-targets-158m-ipo-iambic-seeks-135m-nasdaq-debut",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-09T14:15:32.000Z",
  "source": {
    "name": "Endpoints News",
    "slug": "endpoints-news",
    "url": "https://endpoints.news/city-therapeutics-targets-158m-ipo-iambic-seeks-135m-nasdaq-debut/"
  },
  "original_language": "en",
  "account": null,
  "summary": "Plus news about Alchemist Capital, Newron Pharmaceuticals, Life Biosciences, Onyx Bio and Tecentriq. City Therapeutics charts $158M IPO: The RNAi startup, from former Alnylam Pharmaceuticals executives, is looking to sell 9.72 million shares at $17 ...",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Quartz",
        "title": "City Therapeutics is seeking up to $185 million in a U.S. IPO for its gene-silencing drugs",
        "url": "https://urgent.news/2026/10/09/city-therapeutics-is-seeking-up-to-185-million-in-a-u-s-ipo-for-its",
        "published": "2026-10-09T12:40:25.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}